Boston genetic medicines company nChroma Bio has stopped enrolling and dosing patients in its only clinical trial, an early-stage study of its chronic hepatitis B therapy CRMA-1001, and is restructuring while it weighs strategic alternatives for its other programs. The company announced the move in a LinkedIn post on Wednesday, Nov. 18.[1][2] The restructuring will cut about half of the company’s workforce, Endpoints News and the Boston Business Journal reported, as cited by BioSpace and The Pharma Letter.[1][2]
Related: Watertown Biotech EyePoint to Cut About Half Its Staff After Wet AMD Trial Miss.
What we know
The halted study is a Phase 1/2 trial of CRMA-1001, a liver-directed epigenetic therapy for chronic hepatitis B. It was the company’s lone clinical program.[1] nChroma gave no reason for stopping enrollment and dosing, and it disclosed no clinical results.[2]
The company did not put a figure on the job cuts in its post.[2] It also did not give its headcount to Endpoints News. Its LinkedIn page lists a company size of 51 to 200 employees, so a cut of about half would mean somewhere between roughly 25 and 100 jobs, depending on where the company sits in that range (TBR calculation).[1]
Patients who already received CRMA-1001 will continue to be monitored, the company told Endpoints. ClinicalTrials.gov lists nine participants.[1]
A short run in the clinic
The trial began less than a year ago. nChroma announced on Dec. 16, 2025, that it had received authorization of a clinical trial application to start a first-in-human study of CRMA-1001, and on Jan. 28, 2026, it announced that the first patient had been dosed.[3] At the time, the company said additional enrollment was underway.[1]
The therapy is an epigenetic silencer, designed to switch off hepatitis B viral DNA. The company presented preclinical research on the approach at the American Association for the Study of Liver Diseases meeting in November 2025, and it posted further hepatitis B research as recently as September.[3]
What is left in the pipeline
Beyond CRMA-1001, nChroma has two research-stage programs and one at the candidate-enabled stage, a PCSK9 program for cardiometabolic disease.[1] The company’s remaining programs include a second hepatitis B candidate, The Pharma Letter reported.[2] nChroma has not said which of those programs it will prioritize or what strategic alternatives it is considering.
Why it matters for Boston
The cuts follow a similar move in October by Watertown’s EyePoint, which said it would cut about half its staff after a trial miss. BioSpace’s 2026 layoff tracker, which logged the nChroma cuts on Nov. 19, also lists Charles River Laboratories closing its Worcester site and consolidating at its Shrewsbury location.[1] For more on the region’s companies and jobs, see our Business & Finance coverage.
Sources
- BioSpace: Layoff Tracker: nChroma halves workforce, BioXcel lets execs go (Nov. 19, 2026)
- The Pharma Letter: nChroma Bio stops enrollment and dosing in hepatitis B trial (Nov. 20, 2026)
- nChroma Bio: News & Research, including press releases of Dec. 16, 2025 and Jan. 28, 2026 (accessed Nov. 20, 2026)
Read next in Boston Local News
Boston Local NewsKKR Moves 350 Boston Workers Into Two International Place After Hiring 138 in a Year
Boston Local NewsMass General Has the Nation’s Fifth-Largest Gap Between Tax Breaks and Community Spending, Report Says
Artificial IntelligenceBoston’s Spark Capital Holds a $12 Billion Anthropic Stake, and Mass. Pensions Get a Cut
Most read this week
- Finland Confirms Strike on Russian Warship in Gulf of Finland; Ukraine’s SBU Claims Drone Attack
- Nvidia Earnings, Walmart and Fed Minutes Headline a Busy Week for Wall Street: What to Watch Nov. 16-20
- Strait of Hormuz Insurance Rates Explained: What War-Risk Cover Costs in 2026
- DSA-Backed Candidates Won 106 Races on Nov. 3, Including 8 House Seats: Full Results
- Rare Earth Truce Explained: What the Jan. 10 Deadline Means
Latest
- Congress Nears a Deal to Ban Chinese Cars From the U.S., With Changes to Spare Mercedes-Benz
- Phil Eng Agrees to a Dec. 7 Council Session, Ending the Blue Hill Avenue Subpoena Standoff
- Massport Is Testing Autonomous Wheelchairs and 4 Cleaning Robots at Logan
- MBTA’s Top Two Police Officials Will Retire Nov. 30; Union Warns of ‘Precipice of Chaos’
- MBTA Weekday Ridership Hit 1,041,000 in October, First Time Above 1 Million Since 2020
Get The Boston Report Briefing
Our free weekly email with the most important stories from Boston and the world. Unsubscribe anytime.
Free. We never sell your address. Privacy policy